Sep 30 |
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
|
Sep 23 |
Innate gets FDA clearance for Phase 1 study for IPH4502 ADC candidate
|
Sep 23 |
FDA grants IND clearance for Innate Pharma’s solid tumour trial
|
Sep 23 |
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
|
Sep 12 |
Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript
|
Sep 12 |
Innate Pharma GAAP EPS of -€0.31, revenue of €12.35M
|
Sep 12 |
Innate Pharma Reports First Half 2024 Business Update and Financial Results
|
Sep 9 |
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
|
Sep 5 |
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
|
Sep 4 |
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
|